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in 3D cultures instead of differentiating into mucous and ciliated differ-
entiated cells. These cells can also grow as large colonies when placed 
in soft agar and when such colonies are introduced into the lungs of 
immunosuppressed mice, some colonies develop into squamous cell 
carcinoma and in other animals they develop into adenocarcinoma. 
This suggests that these immortalized and transformed HBECs have 
bronchiolar-alveolar stem-like characteristics that can differentiate into 
squamous cell and adenocarcinoma non small cell lung cancer. 
Stem cells are deﬁned by both their ability to make more stem cells 
(self renewal) and their ability to produce cells that can differentiate. 
Human bronchial epithelial cells expressing cdk4 and hTERT fulﬁll this 
deﬁnition of normal stem cells by continuous self renewal and by hav-
ing the capability of differentiating into both mucous and ciliated epi-
thelial cells. Thus, 3D organotypic cultures bridge standard monolayer 
culture (2D) with those of animal models of lung cancer and should be 
important for developing a fuller understanding of the pathogenesis of 
human lung cancer. In summary, the production of hTERT engineered 
cells offer the possibility of producing tissues to model a variety of 
diseases and aged-related medical conditions.
Targeting Telomerase in Lung Cancer Stem Cells. 
Similar to normal stem cells, cancer stem cells also have the ability to 
self-renew as well as undergo differentiation to give rise to the phe-
notypically diverse types of cancer cells. The implications of this is if 
only a rare subset of tumor stem cells drives tumor formation, then the 
goal of cancer therapy should be to identify this population of cells and 
to develop therapies that target unique mechanisms that are only active 
in cancer stem cells, sparing normal tissue stem cells. As part of our 
anti-telomerase therapeutics program, we have addressed the follow-
ing question: Will telomerase inhibitors not only target the bulk of the 
tumor cell population but also the rarer cancer stem cells? 
Normal stem cells have longer telomeres compared to cancer stem 
cells, thus we believe there may be a window of opportunity to target 
cancer stems cells by inhibiting telomerase and driving telomeres short 
and cells into apoptotic cell death, hopefully without irreversible dam-
age to normal stem cells. While the characteristics of the cancer stem of 
human lung cancer are not presently known, we have examined almost 
all cancer stem cell putative markers. In each case we have observed 
that puriﬁed lung cancer cells with putative markers for cancer stem 
cells are positive for telomerase activity and that an inhibitor currently 
being tested in early stage clinical trials, GRN163L, robustly inhibits 
the activity of telomerase in these sorted populations of cells as well as 
the mass population of cancer cells. 
Lung Cancer Stem Cell Like Properties Are Enriched in Lung 
Cancer Spheroids. 
We have begun to culture lung cancer cells as spheroids on non-ad-
herent culture dishes and have observed that many stem cell markers 
(e.g. Oct 4, Nanog, SOX2) are highly up-regulated when cultured as 
spheroids as opposed to normal adherent cell cultures. When such hu-
man lung spheroids are treated with GRN163L, we observe a decrease 
expression of these stem cell markers. Thus we propose that while can-
cer stem cells are maintained at low numbers in most solid tumors, the 
treatment of lung tumors with GRN163L may shift the stem cell popu-
lation into a depletion mode eventually leading to loss of the putative 
stem cell population. In summary, telomerase is a universal oncology 
target with high tumor speciﬁcity and we propose that anti-telomerase 
therapies (such as GRN163L) may target the cancer stem cell popula-
tion as well as the bulk of the tumor. 
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To address the lung cancer epidemic, beside antitobacco primary 
prevention efforts, early detection and chemoprevention strategies are 
needed. A better understanding of lung carcinogenesis is critical to 
improve chemoprevention strategies. The study of molecular abnor-
malities in preinvasive lesions represent one way to address the critical 
steps of lung tumor development. The identiﬁcation of molecular 
events involved in preinvasive lesions progression could lead to clinical 
studies with new molecular-targeted agents and the development of 
surrogate biomarkers. Such biomarkers are essential to select high-risk 
patients, select chemoprevention strategies and monitor drug efﬁcacy.
While morphological features of the airway mucosa of high risk indi-
viduals are well established, by themselves do not provide a satisfying 
predictive model of lung cancer development. The hypothesis pursued 
here is that molecular characteristics of the airway mucosa contains 
such information and that when applied with epidemiological, morpho-
logical and imaging related data elements, would provide a power-
ful tool to classify subjects at high risk for lung cancer and should 
ultimately personalize the management of lung cancer and reduce the 
overall mortality associated with this disease.
Access to these preinvasive lesions is provided by selection of high-
est risk group, autoﬂuoresence bronchoscopy or other endoscopic 
techniques that improve the sensitivity of detection of preinvasive 
dysplastic bronchial lesions. Morphological features and molecular ab-
normalities of such lesions have been described and can be monitored 
by follow-up bronchoscopies to validate potential chemoprevention 
treatments.
Bronchial specimen obtained from these high risk individuals lead to 
the report of a series of candidate biomarkers. These markers are being 
discovered through a series of methodologies advances that include 
polymerase chain reaction, genome-wide DNA copy number altera-
tions, expression arrays and proteomic strategies such as conventional 
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immunhistochemical analyses, antibody arrays and matrix assisted laser 
desorption ionization mass spectrometry. This could provide molecular 
biomarkers and targets for the detection and treatment of early lung 
cancer. 
Examination of genetic alterations in preinvasive lesions has provided 
valuable information on the development of lung cancer but it has been 
difﬁcult to apply it to clinical practice. Detecting preinvasive changes 
would require recovery of tissue material and extraction of DNA for 
examination, which is not easily obtained non-invasively. Fragments of 
DNA may be recoverable from the serum, but so far, this small amount 
prohibits thorough evaluation in lung cancer detection. Proteins, 
however, are easily obtained from a variety of non-invasive source in-
cluding blood, sputum, and exhaled breath condensate. While examin-
ing the changes in the DNA of tumors can provide clues to changes in 
transformed cell function, examination of the differential expression of 
proteins in malignant cells allows us to see exactly how these genetic 
changes are translated. In this way, a proteomic approach may not only 
allow us to diagnose lung cancers early, it may also give insight into the 
behavior and metastatic potential of these tumors. 
Initial proteomic approaches relied upon antibodies directed at known 
proteins thought to be important in lung cancer development. In 1988, 
Tockman ﬁrst reported a monoclonal antibody directed at a protein that 
could be detected in the sputum of patients at high risk for developing 
lung cancer. This antibody, later determined to be HNRNP A2/B1, was 
90% accurate in predicting patients who would develop lung cancer 
over the next few years (Tockman, 1988}. HNRNP A2/B1 has been 
detected in other biological specimens, including BAL and blood, since 
that report (Fielding, 1999; Fleischhacker, 2001; Mulshine, 2002 }. 
Many other proteins, including COX-2, farnesyl transferase, and EGFR, 
have also been found to be over-expressed in lung cancers (Adjei, 2003; 
Dubinett, 2003; Hasturk, 2002; Hosomi, 2000; Marangolo, 2002}. 
While these proteins are the targets of new therapies for lung cancer, 
they have not been useful as a method of early detection thus far.
The development of Matrix Assisted Laser Desorption Ionization Mass 
Spectroscopy (MALDI MS) has provided a new, powerful technique 
for the study of cancer proteomics (Chaurand, 1999}. A recent study of 
resected tumors demonstrated that this technique was 100% accurate in 
identifying cancer from non-cancer and histological type (Yanagisawa, 
2003}. This technique was also 75% accurate in predicting lymph node 
involvement when compared to light microscopy of resected nodes. 
The pattern of expression of just 15 proteins was able to separate 
patients with good and poor prognosis (median survival 33 versus 6 
months) (Yanagisawa, 2003}. This study demonstrates the powerful po-
tential of MALDI-MS proﬁling not only to diagnose of lung cancer but 
also to provide important information on tumor behavior and prognosis. 
Additionally, it can potentially identify novel proteins involved in the 
disease for further study.
We began characterizing the proteomic proﬁles of the airway mucosa 
from patients with lung cancer because this population is more acces-
sible clinically and because we wanted to further test the feasibility 
to this project in bronchial biopsies (Rahman, 2005}. We identiﬁed 
patterns of protein expression of the airway epithelium (alveolar and 
bronchial) at different stages of tumor progression by tissue-based 
matrix-assisted laser desorption and ionization mass spectrometry 
(MALDI-MS). Based on statistically selected discriminatory proteins 
normal, pre-invasive and invasive lung tissues were classiﬁed to their 
histological subtypes with over 90% accuracy. 
In conclusion, recent advances in the understanding of the molecular 
biology of preinvasive lesions has helped identify many promising 
potential markers of early lesions which will lead to new effective 
biomarkers and chemopreventive strategies in high-risk populations. 
Better selection of individuals at highest risk of lung cancer using 
biomarkers of disease and of genetic susceptibility, may improve their 
positive predictive values, minimize the false positive rates and associ-
ated unnecessary investigations or treatment, as well as reduce the cost 
of the early detection process. 
M11-02 Chemoprevention, Tue, Sept 4, 10:30 - 12:00
Chemoprevention 2007
van Zandwijk, Nico 
Netherlands Cancer Institute, Amsterdam, Neteherlands
Lung cancer is frequently diagnosed at an advanced stage and thus im-
provements in long-term cure have been difﬁcult to achieve. Tobacco 
smoking accounts for more than 80% of the attributable risk for lung 
cancer but also other etiologic factors are being uncovered and its is 
becoming increasingly clear that different preneoplastic pathways exist. 
Major histopathologic changes in the bronchial mucosa that precede the 
development of squamous carcinomas of the lung have been identiﬁed. 
For adenocarcinoma and large cell carcinoma such sequences have 
been less well documented. For adenocarcinoma at least two pathways 
(smoking-related and non-smoking-related) have been suggested. 
Despite smoking cessation, lung cancer risk remains elevated for many 
years and never reaches the level of never smokers(1). In recent years a 
signiﬁcant percentage of newly diagnosed lung cancer occurs in former 
smokers (2,3). And there is no other conclusion that in certain indi-
viduals the carcinogenic process elicited by tobacco smoke continues 
to evolve depite smoking cessation. These observations explain why 
strategies to slow, halt or even reverse the carcinogenic process con-
tinue to gain great interest. Notwithstanding the negative outcome of 
several large comparative trials, chemoprevention continues to show its 
potential to be a major component of lung cancer control. 
Traditional chemoprevention studies with cancer incidence as the 
primary endpoint required many years of follow-up and thousands of 
participants to detect signiﬁcant impact and the interpretation of results 
has been complicated by the fact that in many studies a signiﬁcant 
percentage of participants continued smoking i.e. while intervention 
with retinoids was associated with increased lung cancer incidence a 
potential beneﬁcial effect of retinoids was suggested in former or never 
smokers (4). 
Moreover classical studies with cancer incidence as the endpoint have 
shown how critical it is to select a population signiﬁcantly at risk. In-
dividuals with a 20 pack-year history do not have more than a 10-15% 
lifetime risk for developing lung cancer and therefore recent studies 
have focused on intermediate marker endpoints to identify potential 
useful chemoprevention strategies. Careful analysis of intermediate 
endpoints is another vital issue. Bronchial metaplasia and dysplasia are 
signiﬁcantly related to smoking status. While metaplasia and dysplasia 
can be found in 80% of current smokers, these abnormalities swiftly 
disappear in the majority of individuals, who stop smoking. Prolifera-
tion markers have shown a more constistent pattern and even in the 
absence of squamous metaplasia increased proliferation may remain 
detectable after smoking cessation (5-7). The subgroup of individuals 
showing this phenomenon might be the population suitable for chemo-
prevention studies. 
Epidemiological, experimental and also clinical studies continue to 
provide evidence that antioxidants, anti-inﬂammatory agents, tyrosine 
